istock-629794242xesai-1

Xesai / iStockphoto.com

7 June 2018Big Pharma

GSK completes buyout of Novartis from joint venture

GSK has confirmed that its $13 billion buyout of Novartis from the companies’ consumer healthcare joint venture has been completed following approval from shareholders.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

GSK buys out Novartis in $13bn consumer healthcare deal

27 March 2018 GSK has revealed that it will buy Novartis out of their joint consumer healthcare business.

GSK seeks to boost oncology repertoire with $5.1bn acquisition

3 December 2018 GSK has agreed to buy US oncology company Tesaro for $5.1 billion, in a move designed to strengthen its anti-cancer offering.

GSK and Pfizer sign joint venture, but will demerge after three years

20 December 2018 Pharmaceutical companies GSK and Pfizer yesterday announced that they will combine their consumer health businesses into a new joint venture with sales of approximately £9.8 billion ($12.7 billion).

More on this story

GSK buys out Novartis in $13bn consumer healthcare deal

27 March 2018 GSK has revealed that it will buy Novartis out of their joint consumer healthcare business.

GSK seeks to boost oncology repertoire with $5.1bn acquisition

3 December 2018 GSK has agreed to buy US oncology company Tesaro for $5.1 billion, in a move designed to strengthen its anti-cancer offering.

GSK and Pfizer sign joint venture, but will demerge after three years

20 December 2018 Pharmaceutical companies GSK and Pfizer yesterday announced that they will combine their consumer health businesses into a new joint venture with sales of approximately £9.8 billion ($12.7 billion).

More on this story

GSK buys out Novartis in $13bn consumer healthcare deal

27 March 2018 GSK has revealed that it will buy Novartis out of their joint consumer healthcare business.

GSK seeks to boost oncology repertoire with $5.1bn acquisition

3 December 2018 GSK has agreed to buy US oncology company Tesaro for $5.1 billion, in a move designed to strengthen its anti-cancer offering.

GSK and Pfizer sign joint venture, but will demerge after three years

20 December 2018 Pharmaceutical companies GSK and Pfizer yesterday announced that they will combine their consumer health businesses into a new joint venture with sales of approximately £9.8 billion ($12.7 billion).

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent